SCHEMBL4070469

SCHEMBL4070469

Brc1cccc(CCO[C@H]2CCCCO2)c1

nearest known ligand 0.51

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.45
CA2 P00918 5/20 0.44
CA1 P00915 4/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
TAAR1 Q96RJ0 3/20 0.41
CA12 O43570 1/20 0.40
CA9 Q16790 1/20 0.40
MBTD1 Q05BQ5 1/20 0.39
L3MBTL3 Q96JM7 1/20 0.39
DHFR P00374 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1800977 1.00 KDM4C (0.51) KDM4CL3MBTL1CA2CA1NPC1
SCHEMBL4074819 0.92 KDM4C (0.46) KDM4CL3MBTL1CA2CA1NPC1
SCHEMBL4074827 0.92 KDM4C (0.46) KDM4CL3MBTL1CA2CA1NPC1
SCHEMBL7852875 0.86 CA2 (0.45) KDM4CCA2CA1CA12CA9
SCHEMBL29865973 0.86 CA2 (0.45) KDM4CCA2CA1CA12CA9
SCHEMBL5422297 0.84 KDM4C (0.51) KDM4CL3MBTL1CA2CA1NPC1
SCHEMBL10686057 0.84 KDM4C (0.51) KDM4CL3MBTL1NPC1RAB9AMEN1
SCHEMBL14065688 0.84 KDM4C (0.51) KDM4CL3MBTL1NPC1RAB9AMEN1
SCHEMBL13953759 0.84 KDM4C (0.51) KDM4CL3MBTL1CA2CA1NPC1
SCHEMBL4078714 0.83 KDM4C (0.49) KDM4CL3MBTL1CA2CA1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2074135-A2 SILICON DERIVATIVES FOR PET IMAGING Bayer Schering Pharma AG (DE) 2009-07-01 EP disclosed
US-20090035215-A1 RADIOFLUORINATION BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2009-02-05 US disclosed
EP-1970064-A1 Silicon-derivatives for pet-imaging Bayer Schering Pharma Aktiengesellschaft (DE) 2008-09-17 EP disclosed
EP-1911452-A1 Silicon-derivates for PET-Imaging Bayer Schering Pharma Aktiengesellschaft (DE) 2008-04-16 EP disclosed
WO-2008040441-A2 SILICON DERIVATIVES FOR PET IMAGING BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-04-10 WO disclosed
EP-1908472-A1 Silicon derivatives for PET imaging Bayer Schering Pharma Aktiengesellschaft (DE) 2008-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090035215-A1 RADIOFLUORINATION AFF2, AFF1, NUTF2 KDM4C 2028/4885L3MBTL1 299/4885CA2 2184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.